Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:56:53.257Z.
Calculation as of: 2026-10-06T15:56:53.257Z.
Quote observation: 2026-10-06T15:55:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7de7752a9f7c92cf302168b3adc2b8952dbd3ee015c15fa7e623ade4200d4f53
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$819.99M
PS Ratio
5.15
TTM Avg
3.19
3Y Avg
4.02
5Y Avg
10.18
Market Cap
$858.31M
PS Ratio
29.88
TTM Avg
20.29
3Y Avg
47.07
5Y Avg
47.07
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $831.91M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $838.75M | 113.37 | 174.59 | 129.38 | 129.38 |
| Beta Bionics, Inc. (BBNX)vs › | $846.26M | 7.11 | 8.02 | 9.17 | 9.17 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $819.99M | 5.15 | 3.19 | 4.02 | 10.18 |
| QuidelOrtho Corporation (QDEL)vs › | $847.61M | 0.32 | 0.49 | 0.82 | 1.32 |
| Ardelyx, Inc. (ARDX)vs › | $815.07M | 1.81 | 3.32 | 5.97 | 11.95 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $858.31M | 29.88 | 20.29 | 47.07 | 47.07 |
| InMode Ltd. (INMD)vs › | $804.44M | 2.15 | 2.45 | 3.11 | 6.00 |
| Apnimed, Inc. (APMD)vs › | $800.45M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $798.82M | 6.69 | 6.23 | 9.08 | 36.05 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-30 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
